<DOC>
	<DOC>NCT01265836</DOC>
	<brief_summary>The purpose of this study is to establish the proportion of patients on lipid-lowering pharmacological treatment (statin or combination) reaching the LDL-C goals according to the updated 2004 National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) guidelines.</brief_summary>
	<brief_title>Dyslipidemia Treatment in Thailand and Cardiovascular Outcomes</brief_title>
	<detailed_description>MC MD</detailed_description>
	<mesh_term>Dyslipidemias</mesh_term>
	<criteria>Provision of subject informed consent, Female or male aged = 18 years Patients eligible for treatment of dyslipidemia with statins, according to the current guidelines NCEP ATPIII about Dyslipidemias and Atherosclerosis Prevention Receiving lipidlowering drug treatment for at least 15 days. Involvement in the planning and conduct of the study (applies to either AstraZeneca staff or staff at the study site). Previous enrolment or randomisation of treatment in the present study Participation in a clinical study during the last 90 days</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Dyslipidemia Treatment and Cardiovascular Outcomes</keyword>
</DOC>